tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports

Inhibikase Therapeutics (IKT) Stock News & Sentiment

376 Followers
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
Premium
Ratings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
4d ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
Premium
Ratings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
4d ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
Premium
Company Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
5d ago
8K
IKT
IKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
IKT Upcoming Earnings Report: What to Expect?
19d ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
Premium
Ratings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
2M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
Premium
Market News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2M ago
IKT
WVE
Dynavax, Inhibikase and More: Stocks Trending by Analysts
Premium
Weekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
4M ago
IKT
DVAX
More IKT News >

IKT News on the Web

Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
TipRanks News
Bullish
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
TipRanks News
Bullish
Inhibikase Begins Pivotal Phase 3 Trial in PAH
TipRanks News
Neutral
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)
TipRanks News
Bullish
Stonepine Capital Management, LLC's Strategic Acquisition of Curis Inc Shares
GuruFocus News
Neutral
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
IKT
Sector Average
Media Buzz
This Week5 articles
Weekly Average2.5 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IKT’s Media Buzz Sentiment?
5 articles about IKT were published this week. In an average week, 2.5 articles are published.
    What is IKT’s weekly average amount of articles?
    In an average week, 2.5 articles about IKT are published.
      What is IKT’s News Sentiment?
      100% of articles about IKT were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week